阿戈美拉汀
哈姆德
内科学
科克伦图书馆
随机对照试验
荟萃分析
医学
萧条(经济学)
不利影响
冲程(发动机)
脑卒中后抑郁
评定量表
临床终点
物理疗法
心理学
治疗组和对照组
抗抑郁药
显著性差异
机械工程
发展心理学
宏观经济学
海马体
工程类
经济
作者
Zhong Chen,Jianle Li,Mengshi Liao,Yun He,Chao Dang,Jian Yu,Shihui Xing,Jinsheng Zeng
出处
期刊:International Clinical Psychopharmacology
[Ovid Technologies (Wolters Kluwer)]
日期:2023-10-02
被引量:1
标识
DOI:10.1097/yic.0000000000000509
摘要
Agomelatine is effective in the treatment of depression, but its effect for post-stroke depression (PSD) remains unclear. This study was conducted to compare the efficacy and safety of agomelatine versus SSRIs/SNRIs in treating PSD. We systematically searched Embase, PubMed, Cochrane Library, WanFang Data, China National Knowledge Infrastructure, and Cqvip databases for double-blind randomized controlled studies comparing the efficacy and safety of agomelatine versus SSRIs/SNRIs for PSD until December 2022. The primary efficacy endpoint was the Hamilton Depression Rating Scale (HAMD) score, and the primary safety endpoint was the incidence of overall adverse reactions. Nine studies comprising 857 patients with PSD were included. After 6-12 weeks of treatment, the HAMD score (P = 0.16) and the overall response rates (P = 0.20) in the agomelatine group were comparable to that in the SSRIs/SNRIs group. Participants treated with agomelatine achieved higher Barthel Index scores compared with the SSRIs/SNRIs group (P = 0.02). There was a significantly lower incidence of overall adverse reactions (P = 0.008) and neurological adverse reactions (P < 0.0001) in the agomelatine group. The efficacy of agomelatine for treating PSD is probably comparable to that of SSRIs/SNRIs, and it may improve stroke outcomes with better safety.
科研通智能强力驱动
Strongly Powered by AbleSci AI